Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 27;14(11):774. doi: 10.1038/s41419-023-06298-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Differential expression of PLOD2 gene in ccRCC and normal kidney tissues. B PLOD2 expression is associated with higher tumor stage in ccRCC. C PLOD2 expression is associated with lymphatic metastasis in ccRCC. A–C Complete data are obtained from the UALCAN database. D–F Kaplan–Meier survival analysis of ccRCC patients from the TCGA datasets. Statistical significance was determined by the log-rank test of Kaplan–Meier analysis. G Representative PLOD2 IHC images of paired ccRCC tissue and adjacent tissues. The levels of PLOD2 in a ccRCC microarray from the Shanghai OUTDO Biotech (HKidE180Su02) were determined by immunohistochemical staining with an anti-PLOD2 antibody, as described in the “Methods”. Scale bar: 50 μm (second and fourth column); 200 μm (first and third column). H PLOD2 is highly expressed in ccRCC tissues compared with normal kidney tissue. The PLOD2 staining intensity was scored in 150 cancer tissues and 30 normal tissues, as described in the “Methods”. I Representative images showing high and low PLOD2 staining in the tissue microarray and the survival data of the corresponding patients. The patients included in the microarray were stratified by dichotomizing the PLOD2 expression status in cancer tissues on a continuous score scale of 0–12, with a cut point of 6. J Patients with ccRCC with high PLOD2 expression have significantly reduced overall survival. With a cut-off point of median score, Kaplan–Meier survival analysis was performed. K, L Patients with ccRCC with high PLOD2 expression (PLOD2 high) have significantly increased hazard ratios for death. Patients with ccRCC with low PLOD2 expression were used as the reference to calculate the hazard ratios for death. Statistical significance was assessed using two-tailed t tests. ***p < 0.001, **p < 0.01, *p < 0.05.